|
Horizon Discovery Group plc is a UK biotechnology company based in Cambridge〔(Horizon Discovery | Contact Us ) Retrieved on September 5, 2014〕 founded in 2005 that provides products and services to support research into personalized medicine. Horizon Discovery also has offices in Cambridge, Massachusetts since acquisition of the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus Inc. in June 2014 for £4.74m ($8.0m USD).〔("Horizon Discovery Group plc Completes Acquisition of CombinatoRx Service Business and Assets from Zalicus Inc." ) Press release, 02/06/2014〕 |footnotes = |founder = Prof. Alberto Bardelli, Dr. Chris Torrance}} The company engages in research into human genetic profiles in health and disease as well as the development of targeted therapeutics, with an emphasis on oncology. Using various genome editing technologies, the company modifies the DNA of various cell lines to mimic genetic defects found in the general population which put people at risk of developing specific cancer types, or that predispose them to benefit from a certain cancer treatment. The company supplies products and services hundreds of biotechnology, diagnostic and pharmaceutical companies, and academic research institutes. In September 2013 Horizon announced 2 major collaborations with Sigma-Aldrich and Harvard University, incorporating the companies' respective nuclease genome-editing technologies into Horizon's GENESIS platform. The first collaboration with Sigma-Aldrich saw the licensing of Zinc Finger Nuclease (ZFN) technology, which provides rapid and efficient knock-out of two or more alleles, complementing the precision of Horizon's proprietary rAAV technology. In the collaboration with Harvard University, Horizon licensed the IP for RNA-guided gene editing system CRISPR, which allows the introduction of a single stranded nick in the genome of mammalian cells, allowing specific gene mutations to be created that are not possible with other nuclease technologies. Their Scientific Advisory Board was expanded in 2014 to include CRISPR experts Dr. Emmanuelle Charpentier, Dr. J. Keith Joung, and Dr. Feng Zhang〔("Horizon Discovery Adds Three Eminent CRISPR Experts to its Scientific Advisory Board." ) Press release, 05/08/2014〕 In 2014, Horizon entered into a genetic diagnostic test development collaboration with Transgenomic in which Horizon Diagnostic's quantitative molecular reference standards would be used in all existing and future assays developed. ==GENESIS Genome-Editing Technology== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Horizon Discovery」の詳細全文を読む スポンサード リンク
|